Amendment No. 1 CLINICAL TRIAL AGREEMENT FOR FB-12 PHASE II STUDY By and Between NSABP Foundation, Inc. and Celcuity, Inc.Clinical Trial Agreement • February 16th, 2021 • Celcuity Inc. • Services-medical laboratories
This Amendment No. 1 (the “Amendment”) to the Clinical Trial Agreement for the FB-12 Phase II Study (the “Agreement’) entered into and effective as of May 8, 2017 (the “Effective Date”), by and between NSABP Foundation, Inc., (“NSABP”), and Celcuity, Inc., (“Celcuity”), is effective as of _____________, 2020 (“Amendment Effective Date”).
